This Plain Language Summary of Publication article (PLSP) from Future Oncology evaluated how well an olanzapine-based three-drug combination prevented nausea and vomiting in Japanese patients receiving their first cycle of trastuzumab deruxtecan (T-DXd), with results measured over 21 days from the initial treatment dose.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)’ and was published in Annals of Oncology.

Visit ESMO using the link to read the original article.